Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.49 Mil Enterprise Value: 126.67 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 52/100

Lexicon Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript

Nov 30, 2023 / 02:30PM GMT
Release Date Price: €4.1
Yasmeen Rahimi
Piper Sandler - Senior Research Analyst

Good morning, everyone. Thank you for joining our third day of Piper Healthcare Conference. Really excited to be featuring the team from Lexicon Pharmaceuticals with lots to cover over the next 25 minutes. First of all, congratulations on today's update on progress, enrollment, and start. And we'll talk about that, but just want to acknowledge just the really great news as we kicked off.

Questions & Answers

Yasmeen Rahimi
Piper Sandler - Senior Research Analyst

We'll start first sort of on INPEFA launch because a lot of our investors are paying close attention. And then we'll go to today's update.

I guess the question that a lot of investors have is at this junction, the year's ending, INPEFA got approved with a phenomenal label. You've done a great job winning formula, and you're continuing to do that, and we'll talk about that into 2024. How do you -- why on now? Why at 2024 a very big inflection point for INPEFA that they need to not miss that in be owning ahead? And how do you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot